EUCTR2010-022183-12-IT进行中（未招募）不适用
Phase II study of metronomic oral Vinorelbine plus Bevacizumab as first line treatment for metastatic breast cancer patients - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histologically or cytologically proven diagnosis breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease. • Patients with evaluable or misurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) • Patients may have received chemotherapy as adjuvant treatment provided that metastatic occurred at least 6 months after the completion of adjuvant chemotherapy. • Patients may have had previous hormonal therapy as adjuvant treatment and/or treatment of metastatic disease provided that the patient has progressive disease at study entry. Hormonal therapy must be discontinued prior to study entry, excluding LH-RH analogue. • Patients may have received prior radiotherapy but not to the sites used to assess response. A minimum 4-week interval must have elapsed unless the area involved was < 20% of bone marrow volume in which case the patient may start treatment earlier. • Patients with HER-2/neu overexpressed tumors, are eligible if they had received previous trastuzumab therapy for advanced disease, and/or a treatment with anti HER2 targeted therapy. • Age > 18 and < 70 years old. • Expected survival of > 12 months. • Adequate cardiac function (Resting left ventricular ejection fraction (LVEF) >50% and no documented history of congestive heart failure (CHF), serious arrhythmia,or myocardial infarction (within 6 months); No severe uncontrolled hypertension; No history of venous or arterial thromboembolic events • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: Hemoglobin > 9.0 g/dl Absolute neutrophil count (ANC) >1,500/mm3 Platelet count = 100,000/µl Total bilirubin < 1.5 times the upper limit of normal ALT and AST < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer) PT-INR/PTT < 1.5 x upper limit of normal Serum creatinine < 1.5 x upper limit of normal. no history of nephritic syndrome < one positive urine dipstick reading, and proteinuria less than 150 mg/d;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who have received one or more regimens of chemotherapy for metastatic disease. • History of another malignancy except appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix during the last 10 years. • Malabsorption syndrome or disease affecting significantly gastrointestinal function or major resection of the stomach or proximal small bowel that could affect absorption of oral vinorelbine. • Patients who have a serious, concurrent uncontrolled medical disorder especially congestive heart failure, uncontrolled high-risk hypertension, arrhythmia, angina pectoris (even if it is medically controlled) or previous history of myocardial infarction within 3 months prior to study entry. • History of stroke of history of venous or arterial thromboembolic events in anticoagulation therapy (except of low dose aspirin <325 mg) • Therapeutic anticoagulant agents, nonsteroidal antiinflammatory agents, or more than 325 mg of aspirin daily( prophylactic lowdose anticoagulant agents is permitted). • Major surgery within the previous 4 weeks • Previous treatment with bevacizumab • Patients with brain or leptomeningeal metastases. • Participation in another clinical trial with any investigative drug within 30 days prior to study screening. • Patients with pre-existing motor or sensory peripheral neuropathy > grade 2 according to NCI criteria. • Male patient.
研究者
相似试验
进行中（未招募）
1 期
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapyBreast cancer with bone metastases previously treated by a hormone therapy.MedDRA version: 12.1Level: LLTClassification code 10027475Term: <Manually entered code. Term in E.1.1>EUCTR2009-014497-18-FRPIERRE FABRE MEDICAMENT66
进行中（未招募）
不适用
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapyBreast cancer with bone metastases previously treated by a hormone therapy.MedDRA version: 13.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014497-18-ATPIERRE FABRE MEDICAMENT66
进行中（未招募）
不适用
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor positive breast cancer with bone metastases previously treated by a hormone therapy. - NDEUCTR2009-014497-18-ITPIERRE FABRE MEDICAMENT66
进行中（未招募）
1 期
A clinical study comparing the combination of oral chemotherapy medications vinorelbine plus cyclophosphamide and capecitabine taken orally at lower doses on a continuous regular schedule with paclitaxel given by injection once a week in patients with advanced breast cancer or breast cancer that has spread to other body systems.EUCTR2016-002200-39-ITInternational Breast Cancer Study Group (IBCSG)160
进行中（未招募）
1 期
Study to assess the efficacy and safety of oral vinorelbine in combination with capecitabine in patients suffering from breast cancer previously treated with other chemotherapies (anthracyclines, and taxanes)EUCTR2004-000665-35-ESPierre Fabre Medicament